CPT code 83698 designates a laboratory assay that measures lipoprotein-associated phospholipase A2 (Lp-PLA2) in a patient specimen. Lp-PLA2 is a circulating enzyme associated with vascular inflammation and is used as a biomarker to help assess cardiovascular risk. Nationally, this code matters because it represents a discrete lab-based risk stratification test that can affect patient management decisions and utilization of downstream cardiovascular services.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for Lp-PLA2 testing, typical settings where the service is provided (clinical and hospital laboratories), and the types of benchmarks and policy issues commonly reviewed for lab codes—coverage patterns, reimbursement policies, and coding guidance. The publication also summarizes where to expect variability in payer coverage and highlights common administrative considerations related to laboratory processing and reporting.

This summary is intended to orient clinicians, billing staff, and policy analysts to the clinical purpose of CPT code 83698, the payer landscape, and the kinds of policy and operational details covered in the full publication.